-
公开(公告)号:US09352170B1
公开(公告)日:2016-05-31
申请号:US13754277
申请日:2013-01-30
Applicant: Christina Davis
Inventor: Christina Davis
IPC: A61N5/06
CPC classification number: A61N5/0618 , A61H2201/10 , A61N2005/0663
Abstract: A spectral color and light therapy system is described which is useful in treating mood, anxiety, attention, substance, and/or behavioral disorders. The system utilizes one or more light source which emits visible colored light at a brilliance factor of at least about 2500 and at least one of four colors which are different from each other, said system providing (a) (i) a light source emitting blue light in the range of about 450 to about 475 nm; and (ii) a source emitting green visible light in the range of about 495 nm to about 570 nm; and (b) a light source emitting rose pink light in the range of about 635 nm to about 650 nm; and a light source of peach light in the range of about 590 nm to about 630 nm. Also provided are methods of treating mood, anxiety, attention, substance, and/or behavioral disorders. Methods of treating and/or ameliorating the symptoms of autism spectrum disorders are described.
Abstract translation: 描述了可用于治疗情绪,焦虑,注意力,物质和/或行为障碍的光谱颜色和光疗系统。 该系统利用一种或多种光源,其以至少约2500的亮度因数和彼此不同的四种颜色中的至少一种发出可见的有色光,所述系统提供(a)(i)发射蓝色的光源 在约450至约475nm的范围内的光; 和(ii)发射在约495nm至约570nm范围内的绿色可见光的源; 和(b)在约635nm至约650nm的范围内发射玫瑰红色光的光源; 以及在约590nm至约630nm的范围内的桃光源。 还提供了治疗情绪,焦虑,注意力,物质和/或行为障碍的方法。 描述了治疗和/或改善自闭症谱系障碍症状的方法。
-
12.
公开(公告)号:US09273087B2
公开(公告)日:2016-03-01
申请号:US14599787
申请日:2015-01-19
Applicant: PRIME SYNTHESIS, INC.
Inventor: Marc L. Rothstein , Dianne M. Rothstein , Dan P. Lee
IPC: C07H21/00 , C03C17/32 , C03C11/00 , G01N33/543 , G01N33/552
CPC classification number: C07H21/00 , C03C11/00 , C03C17/32 , C03C17/328 , G01N33/54313 , G01N33/54353 , G01N33/552 , Y10T428/2989 , Y10T428/2996 , Y10T428/2998
Abstract: A method for preparing a crosslinked polymer coated controlled porosity glass (CPG) particle is provided. The method involves mixing CPG particles in a solution comprising polyvinylbenzylchloride and a first solvent at a temperature below 10° C. A second solvent is added and a crosslinking agent is added to the mixture. The first solvent is removed rapidly within 1½ hours of addition of the crosslinking agent. The crosslinking reaction is permitted to proceed and the mixture is then cooled and treated to remove any remaining solvent. The resulting coated CPG particles are washed and dried. Also provided a polymer coated CPG particles using for loading ligand thereon.
Abstract translation: 提供了一种制备交联聚合物涂层控制孔隙玻璃(CPG)颗粒的方法。 该方法包括在低于10℃的温度下将CPG颗粒混合在包含聚乙烯基苄基氯和第一溶剂的溶液中。加入第二溶剂并向混合物中加入交联剂。 第一溶剂在加入交联剂的1小时内迅速除去。 允许交联反应进行,然后将混合物冷却并处理以除去任何残留的溶剂。 将所得涂覆的CPG颗粒洗涤并干燥。 还提供了用于在其上负载配体的聚合物涂覆的CPG颗粒。
-
公开(公告)号:US07803209B2
公开(公告)日:2010-09-28
申请号:US11719967
申请日:2005-09-30
Applicant: Hideyuki Takahashi
Inventor: Hideyuki Takahashi
CPC classification number: C22C12/00 , B22F2003/247 , B22F2998/10 , B22F2999/00 , C22C28/00 , C23C14/3414 , G11B7/266 , B22F9/082 , B22F3/10 , B22F3/24 , B22F2201/11
Abstract: Provided is an Sb—Te alloy sintered compact sputtering target having at least Sb or Te as its primary component, wherein surface roughness Ra is 0.4 μm or less, purity excluding gas components is 4N or more, content of gas components as impurities is 1500 ppm or less, and average crystal grain size is 50 μm or less. With this Sb—Te alloy sintered compact sputtering target, the density of defects having a maximum length of 10 μm or greater arising in a surface finish by machining is 80 or less in an 800 μm square. Thus, the Sb—Te alloy sputtering target structure can be uniformalized and refined, generation of cracks in the sintered target can be inhibited, and generation of arcing during sputtering can be inhibited. Further, surface ruggedness caused by sputter erosion can be reduced in order to obtain a high quality Sb—Te alloy sputtering target.
Abstract translation: 提供一种Sb-Te合金烧结体型溅射靶,其至少具有Sb或Te作为其主要成分,其中表面粗糙度Ra为0.4μm以下,除气体成分以外的纯度为4N以上,作为杂质的气体成分的含量为1500ppm 以下,平均结晶粒径为50μm以下。 对于该Sb-Te合金烧结体型溅射靶,通过机械加工得到的表面光洁度中产生的最大长度为10μm以上的缺陷密度为800μm以下,为80以下。 因此,Sb-Te合金溅射靶结构可以均匀化和精制,可以抑制烧结靶中的裂纹的产生,并且可以抑制溅射期间的电弧放电。 此外,为了获得高品质的Sb-Te合金溅射靶,可以减少由溅射侵蚀引起的表面粗糙度。
-
公开(公告)号:US11535665B2
公开(公告)日:2022-12-27
申请号:US15571708
申请日:2016-05-12
Inventor: Maria P. Limberis , Anna P. Tretiakova , James M. Wilson
Abstract: AAV vectors expressing anti-influenza antibodies are provided. Also described are pharmaceutical compositions useful in delivery same for prophylactic or anti-viral purposes. Methods of delivering such vectors are provided.
-
公开(公告)号:US11197937B2
公开(公告)日:2021-12-14
申请号:US16093420
申请日:2017-04-14
Inventor: Anna P. Tretiakova , James M. Wilson
Abstract: A recombinant adeno-associated virus (rAAV) having an AAV8 capsid which is suitable for intra-retinal injection is provided herein. The rAAV comprises a vector genome packaged within the capsid which contains, operably linked to regulatory elements which direct expression of anti-human vascular endothelial growth factor (VEGF) antigen binding antibody fragment (aVEGF), a coding sequence for aVEGF, wherein the coding sequence is operably linked to regulatory elements which direct expression of the anti-VEGF Fab in the eye. Also provided herein are liquid suspensions containing these rAAV8.aVEGF and methods of using same for treatment of wet AMD and other ocular conditions.
-
公开(公告)号:US10973929B2
公开(公告)日:2021-04-13
申请号:US16075056
申请日:2017-02-02
Inventor: Christian Hinderer , James M. Wilson
Abstract: A suspension useful for AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDUA gene is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating MPSI and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes.
-
公开(公告)号:US10895173B2
公开(公告)日:2021-01-19
申请号:US16465090
申请日:2017-11-22
Applicant: CCm Technologies Limited
Inventor: Peter Hammond
Abstract: A method of driving a turbine, the method comprising: (a) providing solid carbon dioxide; (b) heating the solid carbon dioxide to produce a high pressure carbon dioxide fluid; (c) passing the carbon dioxide over a blade of the turbine; and (d) collecting the carbon dioxide that has passed over the turbine blade; wherein carbon dioxide collected in step (d) is in solid form.
-
公开(公告)号:US10167454B2
公开(公告)日:2019-01-01
申请号:US15122853
申请日:2015-03-09
Inventor: Lili Wang , James M. Wilson
IPC: C12N15/86 , C12N15/861 , C12N15/867 , C12N9/10 , A61K48/00
Abstract: Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis cirrhosis in OTCD patients by administering hOTC.
-
公开(公告)号:US09295642B2
公开(公告)日:2016-03-29
申请号:US14872226
申请日:2015-10-01
Applicant: TRIS Pharma, Inc.
Inventor: Yu-Hsing Tu , Ashok Perumal , Kalyan Kathala
IPC: A61K9/20 , A61K9/22 , A61K9/00 , A61K31/4458
CPC classification number: A61K31/4458 , A61K9/0056 , A61K9/20 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/209 , A61K9/28 , A61K9/284 , A61K9/2846 , A61K9/5026 , A61K47/585
Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
-
20.
公开(公告)号:US11273227B2
公开(公告)日:2022-03-15
申请号:US15766973
申请日:2016-10-07
Inventor: Kathleen Boesze-Battaglia
Abstract: Engineered MREG proteins are described. Further described are viral vectors expressing native or engineered MREG proteins. Further described are compositions containing these vectors or proteins formulated for delivery to the eye. Also provided are methods for delivering these native and engineered MREG proteins to ocular cells for treatment of Stargardt's disease, macular degeneration and other ocular disorders.
-
-
-
-
-
-
-
-
-